Physician profile
Agustus Beck
NPI 1154314797
$28,159.47
in general payments reported to CMS, 2019-2025
43 companies · $2,465 in 2025
The $2,465 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,956 · 2021: $2,396 · 2022: $2,166 · 2023: $2,392 · 2024: $2,938 · 2025: $2,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,794.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $12,672.17 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $1,493.42 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Amgen INC. | $1,294.72 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,247.36 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $968.06 | 2019-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $928.51 | 2019-2025 | |
| Pfizer INC. | $925.32 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $891.23 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $720.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $615.04 | 2022-2025 | Verquvo |
| Esperion Therapeutics, INC. | $589.30 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $497.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $488.37 | 2019-2025 | Opsumit |
| Amarin Pharma, INC. | $462.27 | 2019-2022 | |
| Abbott Laboratories | $411.49 | 2019-2025 | Cardiomems, Jot Dx |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $360.08 | 2023-2025 | |
| Atricure, INC. | $328.83 | 2023-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Regeneron Healthcare Solutions, INC. | $303.47 | 2019-2025 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $301.01 | 2019-2024 | |
| Medtronic, INC. | $277.62 | 2022-2025 | Micra, Linq II, Venaseal |
| Lexicon Pharmaceuticals, INC. | $226.39 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $225.02 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $216.10 | 2023-2025 | Optimizer, Optimizer |
| Astellas Pharma US INC | $211.88 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $188.52 | 2024 | Arcalyst |
| Heartflow, INC. | $151.20 | 2023-2024 | Ffrct |
| Azurity Pharmaceuticals, INC. | $146.59 | 2023-2024 | Edarbyclor, Edarbyclor |
| Alnylam Pharmaceuticals INC. | $141.13 | 2023-2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $134.21 | 2019-2025 | Lifevest |
| Lundbeck LLC | $122.45 | 2019-2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $104.23 | 2021-2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $95.41 | 2019-2022 | |
| Bridgebio Pharma, INC. | $80.48 | 2025 | Attruby |
| Lilly USA, LLC | $79.00 | 2025 | Zepbound, Mounjaro |
| United Therapeutics Corporation | $59.99 | 2021 | |
| Glaxosmithkline, LLC. | $40.67 | 2025 | Shingrix, Arexvy |
| Irhythm Technologies, INC. | $40.15 | 2022 | |
| Itamar Medical INC | $27.08 | 2022-2024 | Watchpatone |
| G Medical Diagnostic Services, INC. | $24.57 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $19.92 | 2023 | Assure Wcd |
| Inspire Medical Systems, INC. | $18.91 | 2024 | Inspire |
| Mannkind Corporation | $16.99 | 2025 | |
| Bardy Diagnostics, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agustus Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.